The Philippine Food and Drug Administration (FDA) has authorized the Department of Health’s (DOH) compassionate special permission (CSP) for Pfizer’s COVID-19 antiviral pill Paxlovid’s generic form.
During a presentation on Monday, January 10, FDA Director Oscar Gutierrez Jr. informed President Rodrigo Duterte of this.
”Na-approve po ng FDA ang application ng DOH para sa compassionate special permit institutional use para maging accessible ang unang generic version ng Paxlovid na ang brand name po ay Bexovid,” says FDA chief Oscar Gutierrez
(The FDA has approved the application of the DOH for a compassionate special permit institutional use to make accessible the first generic version of Paxlovid with the brand name Bexovid.)
Bexovid is the world’s first generic counterpart of Pfizer’s FDA-approved brand Paxlovid. Nirmatrelvir and ritonavir are its generic names.
Because Bexovid is a generic medicine, Gutierrez claims that therapy will be less expensive. The treatment will consist of two medications, nirmatelvir and ritonavir, which will be taken twice a day for five days.
Bexovid is manufactured by Beximco Pharm and will be sold in the Philippines by Biocare Lifescience, according to the FDA commissioner.
In his presentation, Gutierrez stated that the medication reduces the risk of hospitalization or death by 89 percent if administered within three days of the onset of symptoms, and by 88 percent if administered within five days of the onset of symptoms.
With the clearance of CSP, the DOH will be able to make the treatment available to government hospitals.
Gutierrez also stated that the FDA has received two product applications for self-administered COVID-19 test kits, indicating that the agency is investigating the idea of permitting self-test kits in light of the current increase in infections.